Provexis PLC (PXS)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.605p

Buy

0.70p

arrow-down-0.0175p (-2.61%)

Prices updated at 12 Dec 2025, 13:00 GMT

Prices minimum 15 mins delay

Prices in GBX

Provexis PLC is engaged in developing and licensing the proprietary Fruitflow, which is a heart-health functional food ingredient for the functional food sector.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Mr. Charles Dawson Buck

CEO

Mr. Ian Ford

Most recent earnings

31 Mar 2025

Fiscal year end

31 Mar 2025

Employees

-

Head office

2 Blagrave Street

Reading

United Kingdom

RG1 1AZ

+44 7490391888

enquiries@provexis.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Charles Dawson Buck Non-Executive Director, Chairman	-
Dr. Niamh Ann O'Kennedy Executive Director, Chief Scientific Officer	-
Mr. Ian Ford Executive Director, Chief Executive Officer and Company Secretary	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
No data

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.